Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma

Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma

The aim of this investigation is to evaluate the association and potential mechanism between plasminogen activator urokinase (PLAU) and the prognosis of patients with liver hepatocellular carcinoma (LIHC). We verified PLAU expression and its correlation with LIHC patients' prognosis in The Canc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastrointestinal oncology 2023-06, Vol.14 (3), p.1434-1450
Hauptverfasser: Wu, Jiebin, Sun, Min, Li, Zhizhen, Shen, Yang, Wu, Yingjun, Zhang, Hesong, Xu, Zhichao, Gao, Qingxiang
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1450
container_issue 3
container_start_page 1434
container_title Journal of gastrointestinal oncology
container_volume 14
creator Wu, Jiebin
Sun, Min
Li, Zhizhen
Shen, Yang
Wu, Yingjun
Zhang, Hesong
Xu, Zhichao
Gao, Qingxiang
description The aim of this investigation is to evaluate the association and potential mechanism between plasminogen activator urokinase (PLAU) and the prognosis of patients with liver hepatocellular carcinoma (LIHC). We verified PLAU expression and its correlation with LIHC patients' prognosis in The Cancer Genome Atlas (TCGA) database. The interaction network for protein-gene was established in the GeneMania database and the STRING database, and the association between PLAU and immune cells was assessed in Tumor Immune Estimation Resource (TIMER) and TCGA databases. The potential physiological mechanism was elucidated by the Gene Set Enrichment Analysis (GSEA) enrichment assessment. Finally, the individual clinical data of 100 LIHC patients were retrospectively evaluated to further analyze the clinical value of PLAU. The PLAU expression in LIHC tissues was greater than in paracancerous tissues, and LIHC patients with low PLAU expression had better disease-specific survival (DSS), overall survival (OS), and progression free interval (PFI) than those with high PLAU expression. In the TIMER database, the PLAU expression was positively associated with six kinds of infiltrating immune cells: CD4 T, neutrophils, CD8 T, macrophages, B, and dendritic cells, while GSEA enrichment analysis indicated PLAU may impact the biological activities of LIHC by taking part in MAPK and JAK_STAT signaling pathways, angiogenesis, and P53. There were statistically significant differences in T-stage and Edmondson grading between the two groups of patients with high and low expression of PLAU (P
doi_str_mv 10.21037/jgo-23-311
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10331755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2836297913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-57ccb710da4c01632ec2213fa495308ef293bb7345c4d75fc5f72197feff82673</originalsourceid><addsrcrecordid>eNpVUU1v1DAUjBCIVqUn7shHJBTwRxwnJwSr8iGtxAUkbtaLY2ddEjvYzqL-KX4jr91SgS_P1hvNjGeq6jmjrzmjQr25nmLNRS0Ye1Sdc876ulX998d4p6qr265nZ9VlztcUT9NLKvnT6kyoRkgu-Hn1-8o5awqJjmwp_vABsq3LzWrJOkNefIiTDQRM8UcoMRETl8EHO5JfvhyImX3wBmaSC0yWQBjJe0jGzjEA2d0tyd4fbSI7CAbHCRcDKQdUSHEKMft8q75C8TaUfCI-WHxHJJq3GVAVSdHKAs-qJw7mbC_v50X17cPV192nev_l4-fdu31tRENLLZUxg2J0hMZQ1gpuDUYjHGACgnbW8V4MgxKNNM2opDPSKYxOOetcx1slLqq3J951GxY7GnSWYNZr8gukGx3B6_83wR_0FI8aOxFMSYkML-8ZUvy52Vz04vPthyDYuGXNO9HyXvVMIPTVCWpSzDlZ96DDqL5rWWPLmguNLSP6xb_WHrB_OxV_AJ6mqB4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2836297913</pqid></control><display><type>article</type><title>Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Wu, Jiebin ; Sun, Min ; Li, Zhizhen ; Shen, Yang ; Wu, Yingjun ; Zhang, Hesong ; Xu, Zhichao ; Gao, Qingxiang</creator><creatorcontrib>Wu, Jiebin ; Sun, Min ; Li, Zhizhen ; Shen, Yang ; Wu, Yingjun ; Zhang, Hesong ; Xu, Zhichao ; Gao, Qingxiang</creatorcontrib><description>The aim of this investigation is to evaluate the association and potential mechanism between plasminogen activator urokinase (PLAU) and the prognosis of patients with liver hepatocellular carcinoma (LIHC). We verified PLAU expression and its correlation with LIHC patients' prognosis in The Cancer Genome Atlas (TCGA) database. The interaction network for protein-gene was established in the GeneMania database and the STRING database, and the association between PLAU and immune cells was assessed in Tumor Immune Estimation Resource (TIMER) and TCGA databases. The potential physiological mechanism was elucidated by the Gene Set Enrichment Analysis (GSEA) enrichment assessment. Finally, the individual clinical data of 100 LIHC patients were retrospectively evaluated to further analyze the clinical value of PLAU. The PLAU expression in LIHC tissues was greater than in paracancerous tissues, and LIHC patients with low PLAU expression had better disease-specific survival (DSS), overall survival (OS), and progression free interval (PFI) than those with high PLAU expression. In the TIMER database, the PLAU expression was positively associated with six kinds of infiltrating immune cells: CD4 T, neutrophils, CD8 T, macrophages, B, and dendritic cells, while GSEA enrichment analysis indicated PLAU may impact the biological activities of LIHC by taking part in MAPK and JAK_STAT signaling pathways, angiogenesis, and P53. There were statistically significant differences in T-stage and Edmondson grading between the two groups of patients with high and low expression of PLAU (P&lt;0.05). The tumor progression rates were 88% (44/50) and 92% (46/50) respectively in the low and high PLAU groups, with early recurrence rates of 60% (30/50) and 72% (36/50), and median PFS of 29.5 and 23 months, respectively. The COX regression analysis showed PLAU expression and CS and Barcelona Clinic Liver Cancer (BCLC) stages were independent prognostic factors affecting tumor progression in LIHC patients. The decreased expression of PLAU can prolong the DSS, OS, and PFI in LIHC patients, and can be utilized as a novel predictive index. PLAU combined with CS staging and BCLC staging has good clinical value in the early screening and prognosis of LIHC. These results reveal an efficient approach for developing anticancer strategies against LIHC.</description><identifier>ISSN: 2078-6891</identifier><identifier>EISSN: 2219-679X</identifier><identifier>DOI: 10.21037/jgo-23-311</identifier><identifier>PMID: 37435232</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Journal of gastrointestinal oncology, 2023-06, Vol.14 (3), p.1434-1450</ispartof><rights>2023 Journal of Gastrointestinal Oncology. All rights reserved.</rights><rights>2023 Journal of Gastrointestinal Oncology. All rights reserved. 2023 Journal of Gastrointestinal Oncology.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331755/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331755/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37435232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Jiebin</creatorcontrib><creatorcontrib>Sun, Min</creatorcontrib><creatorcontrib>Li, Zhizhen</creatorcontrib><creatorcontrib>Shen, Yang</creatorcontrib><creatorcontrib>Wu, Yingjun</creatorcontrib><creatorcontrib>Zhang, Hesong</creatorcontrib><creatorcontrib>Xu, Zhichao</creatorcontrib><creatorcontrib>Gao, Qingxiang</creatorcontrib><title>Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma</title><title>Journal of gastrointestinal oncology</title><addtitle>J Gastrointest Oncol</addtitle><description>The aim of this investigation is to evaluate the association and potential mechanism between plasminogen activator urokinase (PLAU) and the prognosis of patients with liver hepatocellular carcinoma (LIHC). We verified PLAU expression and its correlation with LIHC patients' prognosis in The Cancer Genome Atlas (TCGA) database. The interaction network for protein-gene was established in the GeneMania database and the STRING database, and the association between PLAU and immune cells was assessed in Tumor Immune Estimation Resource (TIMER) and TCGA databases. The potential physiological mechanism was elucidated by the Gene Set Enrichment Analysis (GSEA) enrichment assessment. Finally, the individual clinical data of 100 LIHC patients were retrospectively evaluated to further analyze the clinical value of PLAU. The PLAU expression in LIHC tissues was greater than in paracancerous tissues, and LIHC patients with low PLAU expression had better disease-specific survival (DSS), overall survival (OS), and progression free interval (PFI) than those with high PLAU expression. In the TIMER database, the PLAU expression was positively associated with six kinds of infiltrating immune cells: CD4 T, neutrophils, CD8 T, macrophages, B, and dendritic cells, while GSEA enrichment analysis indicated PLAU may impact the biological activities of LIHC by taking part in MAPK and JAK_STAT signaling pathways, angiogenesis, and P53. There were statistically significant differences in T-stage and Edmondson grading between the two groups of patients with high and low expression of PLAU (P&lt;0.05). The tumor progression rates were 88% (44/50) and 92% (46/50) respectively in the low and high PLAU groups, with early recurrence rates of 60% (30/50) and 72% (36/50), and median PFS of 29.5 and 23 months, respectively. The COX regression analysis showed PLAU expression and CS and Barcelona Clinic Liver Cancer (BCLC) stages were independent prognostic factors affecting tumor progression in LIHC patients. The decreased expression of PLAU can prolong the DSS, OS, and PFI in LIHC patients, and can be utilized as a novel predictive index. PLAU combined with CS staging and BCLC staging has good clinical value in the early screening and prognosis of LIHC. These results reveal an efficient approach for developing anticancer strategies against LIHC.</description><subject>Original</subject><issn>2078-6891</issn><issn>2219-679X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVUU1v1DAUjBCIVqUn7shHJBTwRxwnJwSr8iGtxAUkbtaLY2ddEjvYzqL-KX4jr91SgS_P1hvNjGeq6jmjrzmjQr25nmLNRS0Ye1Sdc876ulX998d4p6qr265nZ9VlztcUT9NLKvnT6kyoRkgu-Hn1-8o5awqJjmwp_vABsq3LzWrJOkNefIiTDQRM8UcoMRETl8EHO5JfvhyImX3wBmaSC0yWQBjJe0jGzjEA2d0tyd4fbSI7CAbHCRcDKQdUSHEKMft8q75C8TaUfCI-WHxHJJq3GVAVSdHKAs-qJw7mbC_v50X17cPV192nev_l4-fdu31tRENLLZUxg2J0hMZQ1gpuDUYjHGACgnbW8V4MgxKNNM2opDPSKYxOOetcx1slLqq3J951GxY7GnSWYNZr8gukGx3B6_83wR_0FI8aOxFMSYkML-8ZUvy52Vz04vPthyDYuGXNO9HyXvVMIPTVCWpSzDlZ96DDqL5rWWPLmguNLSP6xb_WHrB_OxV_AJ6mqB4</recordid><startdate>20230630</startdate><enddate>20230630</enddate><creator>Wu, Jiebin</creator><creator>Sun, Min</creator><creator>Li, Zhizhen</creator><creator>Shen, Yang</creator><creator>Wu, Yingjun</creator><creator>Zhang, Hesong</creator><creator>Xu, Zhichao</creator><creator>Gao, Qingxiang</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230630</creationdate><title>Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma</title><author>Wu, Jiebin ; Sun, Min ; Li, Zhizhen ; Shen, Yang ; Wu, Yingjun ; Zhang, Hesong ; Xu, Zhichao ; Gao, Qingxiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-57ccb710da4c01632ec2213fa495308ef293bb7345c4d75fc5f72197feff82673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Wu, Jiebin</creatorcontrib><creatorcontrib>Sun, Min</creatorcontrib><creatorcontrib>Li, Zhizhen</creatorcontrib><creatorcontrib>Shen, Yang</creatorcontrib><creatorcontrib>Wu, Yingjun</creatorcontrib><creatorcontrib>Zhang, Hesong</creatorcontrib><creatorcontrib>Xu, Zhichao</creatorcontrib><creatorcontrib>Gao, Qingxiang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of gastrointestinal oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Jiebin</au><au>Sun, Min</au><au>Li, Zhizhen</au><au>Shen, Yang</au><au>Wu, Yingjun</au><au>Zhang, Hesong</au><au>Xu, Zhichao</au><au>Gao, Qingxiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma</atitle><jtitle>Journal of gastrointestinal oncology</jtitle><addtitle>J Gastrointest Oncol</addtitle><date>2023-06-30</date><risdate>2023</risdate><volume>14</volume><issue>3</issue><spage>1434</spage><epage>1450</epage><pages>1434-1450</pages><issn>2078-6891</issn><eissn>2219-679X</eissn><abstract>The aim of this investigation is to evaluate the association and potential mechanism between plasminogen activator urokinase (PLAU) and the prognosis of patients with liver hepatocellular carcinoma (LIHC). We verified PLAU expression and its correlation with LIHC patients' prognosis in The Cancer Genome Atlas (TCGA) database. The interaction network for protein-gene was established in the GeneMania database and the STRING database, and the association between PLAU and immune cells was assessed in Tumor Immune Estimation Resource (TIMER) and TCGA databases. The potential physiological mechanism was elucidated by the Gene Set Enrichment Analysis (GSEA) enrichment assessment. Finally, the individual clinical data of 100 LIHC patients were retrospectively evaluated to further analyze the clinical value of PLAU. The PLAU expression in LIHC tissues was greater than in paracancerous tissues, and LIHC patients with low PLAU expression had better disease-specific survival (DSS), overall survival (OS), and progression free interval (PFI) than those with high PLAU expression. In the TIMER database, the PLAU expression was positively associated with six kinds of infiltrating immune cells: CD4 T, neutrophils, CD8 T, macrophages, B, and dendritic cells, while GSEA enrichment analysis indicated PLAU may impact the biological activities of LIHC by taking part in MAPK and JAK_STAT signaling pathways, angiogenesis, and P53. There were statistically significant differences in T-stage and Edmondson grading between the two groups of patients with high and low expression of PLAU (P&lt;0.05). The tumor progression rates were 88% (44/50) and 92% (46/50) respectively in the low and high PLAU groups, with early recurrence rates of 60% (30/50) and 72% (36/50), and median PFS of 29.5 and 23 months, respectively. The COX regression analysis showed PLAU expression and CS and Barcelona Clinic Liver Cancer (BCLC) stages were independent prognostic factors affecting tumor progression in LIHC patients. The decreased expression of PLAU can prolong the DSS, OS, and PFI in LIHC patients, and can be utilized as a novel predictive index. PLAU combined with CS staging and BCLC staging has good clinical value in the early screening and prognosis of LIHC. These results reveal an efficient approach for developing anticancer strategies against LIHC.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>37435232</pmid><doi>10.21037/jgo-23-311</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2078-6891
ispartof Journal of gastrointestinal oncology, 2023-06, Vol.14 (3), p.1434-1450
issn 2078-6891
2219-679X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10331755
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T12%3A16%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20urokinase-type%20plasminogen%20activator%20combined%20with%20clinical%20stage%20and%20Barcelona%20Clinic%20Liver%20Cancer%20stage%20on%20the%20prognosis%20of%20patients%20with%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20gastrointestinal%20oncology&rft.au=Wu,%20Jiebin&rft.date=2023-06-30&rft.volume=14&rft.issue=3&rft.spage=1434&rft.epage=1450&rft.pages=1434-1450&rft.issn=2078-6891&rft.eissn=2219-679X&rft_id=info:doi/10.21037/jgo-23-311&rft_dat=%3Cproquest_pubme%3E2836297913%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2836297913&rft_id=info:pmid/37435232&rfr_iscdi=true